Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults

MONTRÉAL, April 8, 2021 /CNW/ - Teva Canada, a subsidiary of Teva Pharmaceutical Industries Ltd., today announced the launch and availability of a new autoinjector for AJOVY® (fremanezumab). AJOVY® is a subcutaneous injection for the preventive treatment of migraine in adults who have at least four migraine days per month. When launched in 2020, AJOVY® was available in a prefilled syringe only. The product is now available in two latex-free1 formats: a new autoinjector and a prefilled syringe.

NewsGuest UserApril 8, 2021Teva Canada, treatment, Migraine

Teva Canada Amplifies Commitment to Canadian Caregivers - Introduces new resources to support and improve mental health of Caregivers

TORONTO, April 6, 2021 /CNW/ - Extending its ongoing commitment to caregivers through the Caregiver-Friendly Pharmacy (CFP) program, and recognizing the significant toll COVID-19 has had on the caregiver community over the past year, Teva Canada today unveiled new resources and programming to support the mental health challenges caregivers often experience.

NewsGuest UserApril 6, 2021Teva Canada, resources, caregiver